Blog

Monoclonal antibodies (mAbs), particularly IgGs, are among the most successful therapeutic proteins used in oncology, autoimmune, and infectious disease indications. One important attribute affecting their clinical performance is N-linked glycosylation at Asn-297 in the CH2 domain of the Fc region.

The 13th Antibody Industrial Symposium 2025 was held in Tours, France, from June 25-26. This event covers the latest advances and associated challenges in the field of therapeutic antibodies and their derivatives, recombinant proteins and other biomedicines, from R&D and into clinical phases. Po

hubXchange's Antibody Drug Conjugates Therapeutics Xchange and Antibody Therapeutics Xchange were held in Boston, MA on June 18, 2025, and June 23, 2025, respectively.

The BIO International Convention 2025 was held in Boston, MA from June 16-19 It is the largest event for biotechnology with 20,000 industry leaders in attendance, sharing the latest advancements in the industry.

World ADC Asia 2025 was held in Incheon, South Korea, on June 10-12, 2025. Asia is fast becoming a global leader in ADC innovation, with first-in-class ADCs, dual payloads, bispecifics, TCE-ADCs, and advanced linkers.

Antibody Engineering & Therapeutics Europe 2025 was held in Basel, Switzerland, on 10-12 June 2025.

Mammalian cell lines are the preferred hosts for producing recombinant proteins that require complex folding, post-translational modifications (PTMs), and secretion. Their ability to perform glycosylation and phosphorylation makes them ideal systems for producing biologically active proteins, especially those used in diagnostics, therapeutics, and advanced biomedical research.

In mammals, antibodies are classified into five major isotypes: IgA, IgD, IgE, IgG, and IgM. Each isotype is defined by the heavy chain it contains: alpha (IgA), delta (IgD), epsilon (IgE), gamma (IgG), or mu (IgM). These structural differences in the heavy chains determine the antibody's function, tissue localization, and role in the immune response.

DOI: 10.1093/ilar.46.3.258Introduction to Polyclonal AntibodiesPolyclonal antibodies(pAbs) are produced by different B lymphocytes and recognize different epitopes of a single antigen. They can be generated in large quantities and rapidly (within several months of initiating immunizations), an

Affinity maturation is a process of improving antibody affinity and binding interactions to target antigen. This is done naturally in vivo through mechanisms of somatic hypermutation and clonal selection in mammalian B cells but can also be achieved in vitro by artificial mutagenesis introduction and selection.

Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses.

In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol